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Azole-resistance in Aspergillus fumigatus is an emerging worldwide
threat as it precludes the use of one of the 3 major classes of
antifungal drugs to treat chronic and invasive aspergillosis [1]. In
addition to the well-known environmental emergence of azole-
resistant A. fumigatus strains, associated with the use of fungi-
cides in agriculture [2,3], the development of in-host resistance,
facilitated by medical antifungal use, has been described [4]. In-
vestigations involving linked sets of (isogenic) clinical isolates of A.
fumigatus sequentially recovered from individual patients, are
extremely important in order to improve our understanding of
how azole resistance develops in-host. Here we present the whole
genome sequences of 13 clinical isogenic A. fumigatus isolates.
These isolates were cultured from a single patient suffering from
invasive aspergillosis over a period of 2 years. This patient un-
derwent a wide range of antifungal therapies and the resultant
isolates acquired multiple azole resistance in-host during the
course of infection. The data presented here is related to our
research paper titled “In-host microevolution of Aspergillus fumi-
gatus: a phenotypic and genotypic analysis” which describes the
phenotypic characterisation of these clinical isolates [5]. The raw
sequence data was deposited in the NCBI Sequence Read ArchiveP.E. Verweij).
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In this article, we present the raw whole genome sequences of 13 clinical isolates of Aspergillus
fumigatus. These isolates were cultured from clinical specimens obtained from a single patient over a
period of 2 years. This patient was diagnosed with chronic granulomatous disease as well as severe
chronic obstructive pulmonary disease and allergic bronchopulmonary aspergillosis [6]. This patient
suffered from various episodes of invasive aspergillosis. A wide range of therapies, including azole
monotherapy and azole combination therapy with echinocandins, were administered over the 2 year
period, but unfortunately the patient died from the infection. The 13 A. fumigatus isolates had acquired
high levels of itraconazole and posaconazole resistance during the course of infection, as well as
varying degrees of voriconazole resistance [5]. These 13 isolates were subjected to whole genome
sequencing and the raw sequence data are presented in this article.
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2.1. Origin of fungal isolates
The 13 clinical isolates sequenced in this article were isolated from a male adult patient diagnosed
with X-linked chronic granulomatous disease. The patient was also diagnosed with severe chronic
obstructive pulmonary disease (Gold IV) and allergic bronchopulmonary aspergillosis. The patient
suffered from 3 episodes of invasive aspergillosis and developed an aspergilloma which, due to their
poor respiratory condition, could not be surgically removed. The patient was prophylactically treated
with interferon-gamma, trimethoprim-sulphamethoxazole and itraconazole. Between June and
December 2011, the patient was treated with itraconazole and subsequently voriconazole in combi-
nationwith an echinocandin (caspofungin or anidulafungin). Isolate V130-15was collected on 22/11/11
from ﬂuid around the right shoulder and isolates V130e14, V130e18 and V130-54 were collected from
pus in the right shoulder on 25/11/11. Between December 2011 and January 2013, the patient was
treated with a variety of therapies consecutively, namely liposomal amphotericin B, itraconazole, and
anidulafungin in combinationwith voriconazole. Between August and December 2013, the patient was
treatedwith posaconazole, followed by posaconazole in combination therapywithmicafungin. Isolates
V157e39, V157e40, V157e47, V157e48 and V157-62 were collected from bronchoalveolar lavage ﬂuid
(BALf) on 9/12/13. Isolates V157e59, V157e60 and V157-61 were collected from BALf on 12/12/13; and
isolate V157-80 was collected from BALf on 19/12/13. Unfortunately, fungal eradication was not ach-
ieved, and the patient died from his infection.
The isolates were cultured and morphologically identiﬁed as A. fumigatus at Radboud University
Medical Centre, Nijmegen, the Netherlands [6].2.2. Fungal culture
A. fumigatus conidia from glycerol stocks frozen at 80 C were spread onto Sabouraud dextrose
agar in T75 culture ﬂasks (Greiner Bio-One, Germany), and incubated at 37 C. After 7 days, conidia
were harvested via immersion in 30 mL phosphate buffered saline (PBS) (Thermo Fisher Scientiﬁc, UK)
containing 0.05% Tween-80 (Thermo Fisher Scientiﬁc, UK). In speciﬁc cases, conidia were inoculated in
liquid glucose minimal media and incubated overnight at 37 C rotating at 200 rpm. Mycelial mass was
subsequently harvested using vacuum ﬁltration and used for DNA isolation.2.3. Whole genome sequencing
DNA was extracted from either conidia or mycelia. Conidia or mycelia were suspended in TE buffer
(pH 8, 1% SDS, 2% Triton X100, 100mM NaCl) and the resultant suspension was shaken for 30 min at
70 C. DNA was extracted using phenol/chloroform extraction and puriﬁed using the QIAamp DNA
BloodMini kit (Qiagen, Germany). A fragmented genomic DNA library was prepared using a Nextera XT
DNA sample preparation kit (Illumina, USA). Sequencing was performed in a paired end 2150 bp
mode using an Illumina NextSeq 500 machine (Illumina, USA).2.4. Location of raw sequence data
The raw sequence data was deposited in the NCBI Sequence Read Archive (https://www.ncbi.nlm.
nih.gov/sra), under BioProject ID number PRJNA528395. The BioSample numbers for each isolates
whole genome sequence are as follows: SAMN11180820 (V130-15); SAMN11180821 (V130-14);
SAMN11180822 (V130-18); SAMN11180823 (V130-54); SAMN11180824 (V157-39); SAMN11180825
(V157-40); SAMN11180826 (V157-47); SAMN11180827 (V157-48); SAMN11180828 (V157-62);
SAMN11180829 (V157-59); SAMN11180830 (V157-60); SAMN11180831 (V157-61); SAMN11180832
(V157-80).
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